115 related articles for article (PubMed ID: 14636885)
1. Bcr-Abl-mediated molecular mechanism for apoptotic suppression in multipotent haemopoietic cells: a role for PKCbetaII.
Xenaki D; Pierce A; Underhill-Day N; Whetton AD; Owen-Lynch PJ
Cell Signal; 2004 Feb; 16(2):145-56. PubMed ID: 14636885
[TBL] [Abstract][Full Text] [Related]
2. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl.
Carlesso N; Frank DA; Griffin JD
J Exp Med; 1996 Mar; 183(3):811-20. PubMed ID: 8642285
[TBL] [Abstract][Full Text] [Related]
3. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members.
Ilaria RL; Van Etten RA
J Biol Chem; 1996 Dec; 271(49):31704-10. PubMed ID: 8940193
[TBL] [Abstract][Full Text] [Related]
4. Abl protein kinase abrogates the response of multipotent haemopoietic cells to the growth inhibitor macrophage inflammatory protein-1 alpha.
Wark G; Heyworth CM; Spooncer E; Czaplewski L; Francis JM; Dexter TM; Whetton AD
Oncogene; 1998 Mar; 16(10):1319-24. PubMed ID: 9546433
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
6. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation.
Barnes K; McIntosh E; Whetton AD; Daley GQ; Bentley J; Baldwin SA
Oncogene; 2005 May; 24(20):3257-67. PubMed ID: 15735728
[TBL] [Abstract][Full Text] [Related]
7. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells.
Spiekermann K; Pau M; Schwab R; Schmieja K; Franzrahe S; Hiddemann W
Exp Hematol; 2002 Mar; 30(3):262-71. PubMed ID: 11882364
[TBL] [Abstract][Full Text] [Related]
8. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
[TBL] [Abstract][Full Text] [Related]
10. Bcr-Abl protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation.
Pierce A; Spooncer E; Wooley S; Dive C; Francis JM; Miyan J; Owen-Lynch PJ; Dexter TM; Whetton AD
Oncogene; 2000 Nov; 19(48):5487-97. PubMed ID: 11114726
[TBL] [Abstract][Full Text] [Related]
11. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
Shuai K; Halpern J; ten Hoeve J; Rao X; Sawyers CL
Oncogene; 1996 Jul; 13(2):247-54. PubMed ID: 8710363
[TBL] [Abstract][Full Text] [Related]
12. p210 Bcr-Abl expression in a primitive multipotent haematopoietic cell line models the development of chronic myeloid leukaemia.
Pierce A; Owen-Lynch PJ; Spooncer E; Dexter TM; Whetton AD
Oncogene; 1998 Aug; 17(5):667-72. PubMed ID: 9704934
[TBL] [Abstract][Full Text] [Related]
13. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells.
Hoover RR; Gerlach MJ; Koh EY; Daley GQ
Oncogene; 2001 Sep; 20(41):5826-35. PubMed ID: 11593388
[TBL] [Abstract][Full Text] [Related]
14. Role of the C-terminal actin binding domain in BCR/ABL-mediated survival and drug resistance.
Underhill-Day N; Pierce A; Thompson SE; Xenaki D; Whetton AD; Owen-Lynch PJ
Br J Haematol; 2006 Mar; 132(6):774-83. PubMed ID: 16487179
[TBL] [Abstract][Full Text] [Related]
15. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.
Chai SK; Nichols GL; Rothman P
J Immunol; 1997 Nov; 159(10):4720-8. PubMed ID: 9366395
[TBL] [Abstract][Full Text] [Related]
16. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.
Klejman A; Schreiner SJ; Nieborowska-Skorska M; Slupianek A; Wilson M; Smithgall TE; Skorski T
EMBO J; 2002 Nov; 21(21):5766-74. PubMed ID: 12411494
[TBL] [Abstract][Full Text] [Related]
17. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
Xie S; Wang Y; Liu J; Sun T; Wilson MB; Smithgall TE; Arlinghaus RB
Oncogene; 2001 Sep; 20(43):6188-95. PubMed ID: 11593427
[TBL] [Abstract][Full Text] [Related]
18. Catalytic-dependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling.
Yu WM; Hawley TS; Hawley RG; Qu CK
Oncogene; 2003 Sep; 22(38):5995-6004. PubMed ID: 12955078
[TBL] [Abstract][Full Text] [Related]
19. In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.
Kindler T; Breitenbuecher F; Kasper S; Stevens T; Carius B; Gschaidmeier H; Huber C; Fischer T
Leukemia; 2003 Jun; 17(6):999-1009. PubMed ID: 12764361
[TBL] [Abstract][Full Text] [Related]
20. High Bcr-Abl expression prevents the translocation of Bax and Bad to the mitochondrion.
Keeshan K; Cotter TG; McKenna SL
Leukemia; 2002 Sep; 16(9):1725-34. PubMed ID: 12200687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
